HEPA
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. insider trading
Insiders at Hepion Pharmaceuticals, Inc. have been buying its stock on the open market. The largest purchase in the last 30 days was Fisher Danina (Director) buying $10K of HEPA, filed Oct 02, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $10K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 29, 2026
From SEC filings · last 30 days
Recent HEPA insider transactions
Fisher DaninaDirector
Bought 200,000 sh at $0.05 · Sep 29, 2026
$10K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
HEPA insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded HEPA on the open market: 4 purchases worth $350K and 0 sales. In the last four quarters alone: 4 purchases ($350K) and 0 sales, by 3 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | +$350K4 buys | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | — | |
| Q3 2024 | — | — |
- Largest purchase
- +$200K of HEPA by LoPriore Vincent S (Executive Chairman · Director) on Apr 21, 2026.
Open-market transactions through Jun 30, 2026most recent first
LoPriore Vincent S
Executive Chairman · Director
+$200K
Apr 21, 2026
5,000,000 sh · $0.04
Purcell Michael J.
Director
+$50K
Apr 21, 2026
1,250,000 sh · $0.04
LoPriore Vincent S
Executive Chairman · Director
+$50K
Apr 21, 2026
1,250,000 sh · $0.04
Appajosyula Sireesh
Director
+$50K
Apr 21, 2026
1,250,000 sh · $0.04
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Apr 21, 2026 | LoPriore Vincent SExecutive Chairman · Director | 5,000,000 | $0.04 | +$200K |
| Apr 21, 2026 | Purcell Michael J.Director | 1,250,000 | $0.04 | +$50K |
| Apr 21, 2026 | LoPriore Vincent SExecutive Chairman · Director | 1,250,000 | $0.04 | +$50K |
| Apr 21, 2026 | Appajosyula SireeshDirector | 1,250,000 | $0.04 | +$50K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check HEPA — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Hepion Pharmaceuticals, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are HEPA insiders buying or selling?
- Between Sep 29, 2026 and Sep 29, 2026, 1 Hepion Pharmaceuticals, Inc. insider made 1 open-market purchase worth $10K and no sales, a net purchase of $10K.
- How much HEPA stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 3 Hepion Pharmaceuticals, Inc. insiders made 4 open-market purchases worth $350K and no sales. In the four quarters to Jun 30, 2026: 4 purchases ($350K) and no sales. The largest purchase was LoPriore Vincent S buying $200K on Apr 21, 2026.
- What was the largest recent HEPA insider trade?
- Fisher Danina (Director) bought $10K of HEPA stock on Sep 29, 2026 at about $0.05 a share.
- When did an insider last buy HEPA shares?
- The most recent open-market purchase on file is Fisher Danina (Director) buying $10K on Sep 29, 2026.
- Where does HEPA insider trading data come from?
- From the Form 4 filings Hepion Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.